Introduction
For more than two years, people have been struggling to fight COVID-19.
Advanced modern medical technology has been tested amid the emergence of
new variants around the world whenever the long tunnel seems end soon.
For now, the global pharmaceutical industry and medical academia are working
to build an effective virus reponse system, instead of just developing medicine
and vaccines for preventing the pandemic.
The reasons are that new types of infection can approach the global humanity,
and that it is impossible to rule out the possibility of appearing a new birus more
contagious than COVID-19.
The interval of new epidemics has become shortened, and this further exacerbates
the crisis. From the beginning of the 2000s, a variety of pandemics such as SARS,
New Influenza and MERS susequently hit the world. For now, the world is coping
with a poweorful COVID-19.
Despite formidable obstacles set by the pandemic, interest in epidemiological
sutdies has been stronger than ever before. Importantly, it is necessary to suggest
a new direction and strategy of carrying out new epidemiological studies aimed to
overcome COVID-19 wisely and respond to the second pandemic crisis. This can
be achieved by promoting cooperation between the government, academia
and business entities.
In this regard, the Financial News and Korea Research Institute of Chemical
Technology will host the 14th Seoul International New Pharmaceuticals Forum
to discuss the parth forward and future tasks of epidemiological research.
Overview
Title : The 14th Seoul International New Pharmaceuticals Forum
Theme : Direction and Strategy of Future Epidemiological Studies in the Era of Post-pandemic
Date : On Wednesday, June 15th, 2022 (09:00 ~ 12:00)
Venue : Park Ballroom, Conrad Seoul (5F)
Hosts : The Financial News,
Korea Research Institute of Chemical Technology
Sponsors : Ministry of Health and Welfare,
Ministry of Science and ICT, Ministry of Food and Drug Safety,
Korea Pharmaceutical and Bio-Pharma Manufacturers Association,
Korea Biotechnology Industry Organization,
Korea Research-based Pharma Industry Association
Contact : Seoul International New Pharmaceuticals Forum Secretaria
Tel. 02-6965-0016 / Mail. info@fnmice.com
Time |
Section |
Program |
||
08 : 00 - 09 : 00 |
Registration |
|||
09 : 00 - 09 : 30 |
Opening |
<Opening Remarks> Byun, Dong Shik President, The Financial News <Welcoming Remarks> Yi, Mi Hye President, Korea Research Institute of Chemical Technology <Congratulatory Remarks> Oh, Yu Kyung Minister, Food and Drug Safety Peck, Kyong Ran Commissioner, Korea Disease Control and Prevention Agency |
||
09 : 30 - 10 : 00 |
Keynote |
<Vaccine Pradigm Shift in the Post-Corona Era> Seong, Baik Lin Distinguished Professor, Yonsei University College of Medicine/ Director General, Vaccine Innovative Technology ALliance(VITAL)- Korea |
||
10 : 00 - 10 : 20 |
Speech |
<Antiviral drugs, essential for pandemic and epidemic preparedness> Johan Neyts Professor, KU Leuven |
||
10 : 20 - 10 : 40 |
<Prevention and treatment strategies for endemic> Cheon, Eun Mi Professor, Ewha Womans University of Medicine |
|||
10 : 40 - 11 : 00 |
<Priorities for drug discovery in global health> Ken Duncan Deputy Director, Discovery & Translational Sciences, Bill & Melinda Gates Foundation |
|||
11 : 00 ~ 12 : 00 |
Panel Discussion |
[Moderator] Kim, Yeon Soo Dean, Graduate School of Drug Discovery & Development, Chungnam National University
[Panelists] Lee, Byung Hee Director, Bioscience Technology Division, Ministry of Science and ICT
Kang, Joo Hye Director, Planning and Coordination Division ,
Ministry of Food and Drug Safety
Cheon, Eun Mi Professor, Ewha Womans University of Medicine
Choi, Gil Don Director, Therapeutics & Biotechnology Division
Han, Tae Dong Director, Dong-A ST Research Institute |
||
12 : 00 ~ 13 : 00 |
Luncheon |
-
Seong, Baik Lin
Distinguished Professor, Yonsei University College of Medicine & Director General, Vaccine Innovative Technology ALliance(VITAL)- Korea
-
Johan Neyts
Professor, KU Leuven
-
Ken Duncan
Deputy Director, Discovery & Translational Sciences, Bill & Melinda Gates Foundation
-
Cheon, Eun Mi
Professor, Ewha Womans University Mokdong Hostpital
-
Kim, Yeon Soo
Dean, Graduate School of New Drug Discovery & Development, Chungnam National University
-
Lee, Byung Hee
Director, Life Technology Division, Ministry of Science and ICT
-
Kang, Joo Hye
Head, Planning and Coordination Division, Ministry of Food and Drug Safety
-
Choi, Gil Don
General Director, Therapeutics & Biotechnology Division, Korea Research Institute of Chemical Technology
-
Han, Tae Dong
Director, Dong-A ST New Drug Research Center

[Education] Seoul National University, College of Pharmacy Department of Pharmacy: Bachelor KAIST Biology Engineering Degree: Master MIT Biology Degree: Ph.D. [Career]


Ken Duncan is Deputy Director of Discovery & Translational Sciences within the Global Health Program of the Bill & Melinda Gates Foundation. He leads the foundation’s efforts in drug discovery across therapeutic areas currently including TB, malaria, antivirals and contraception. He recently coordinated the drug discovery response to COVID-19 then developed and is implementing a strategy for pandemic preparedness, working together with other funding agencies, to identify safe, effective agents that can be deployed in low-resource settings. He established the TB Drug Accelerator, a new model of public-private collaboration, which aims to discover drug candidates that will contribute to a short-acting TB therapy. He played a major role in launching the Global Health Drug Discovery Institute in Beijing, China. He serves on the Selection Committee of the Global Health Innovative Technology Fund in Japan. Before joining the foundation in 2007, he spent 16 years in the pharmaceutical industry, most recently as Director, Diseases of the Developing World at GlaxoSmithKline. During that time, he helped establish the Global Alliance for TB Drug Development and served on its Scientific Advisory Committee for six years. Dr. Duncan obtained a BSc in Molecular Biology from the University of Edinburgh and a PhD from the University of Glasgow, and completed Postdoctoral Research Fellowships at the University of Glasgow, Massachusetts Institute of Technology and Harvard Medical School.


[Education] BS degree, Seoul National University, Korea (1982) MS degree, Seoul National Iniversity, Korea (1984) Ph.D. degree, Seoul National University, Korea (1989) [Career]




[Career]